Moritani Sueyoshi, Takenobu Masao, Yasunaga Masakazu, Kawamoto Katsuyuki, Fujii Taihei, Kitano Hiroya
Omi Medical Center, Center for Otolaryngology, Head and Neck Thyroid Surgery, Japan.
Omi Medical Center, Center for Otolaryngology, Head and Neck Thyroid Surgery, Japan.
Auris Nasus Larynx. 2025 Apr;52(2):127-131. doi: 10.1016/j.anl.2024.12.012. Epub 2025 Jan 31.
The AJCC-8 staging system for papillary thyroid carcinoma (PTC) excludes certain lymph node characteristics from stage determinants due to insufficient evidence of their prognostic impact. This study aimed to examine the influence of gross extranodal extension (N-Ex) on survival and recurrence by comparing outcomes of extrathyroidal extension (T-Ex) and N-Ex cases.
Patients with PTC who underwent initial surgical treatment and had T-Ex or N-Ex were selected. Their survival and recurrence rates were compared, focusing on age and stage classification. Patients younger than 55 years without distant metastasis (DM) are classified as Stage I, regardless of T-Ex or N-Ex. Patients aged 55 years or older without DM are classified as Stage II if they have N-Ex without T-Ex and Stage III or IVA if they have T-Ex. The prognoses of the T-Ex and N-Ex groups stratified by age were compared. Using the T-classification by organ involvement, older patients with N-Ex were subgrouped, and their prognoses were compared with those of the T-Ex group.
The study included 183 T-Ex and 50 N-Ex without T-Ex cases. The disease-specific survival (DSS) and disease-free survival (DFS) of the two groups did not differ for the younger patients without distant metastases (Stage I in both groups). For the older patients without distant metastasis, the 10-year DSS was 80.6% and 48.5% for Stages III and IVA (with T4bAnyNM0; T-Ex group) and 74.7% for Stage II (with T1-3N-ExM0; N-Ex group). The 10-year DFS were 68.2%, 0%, and 64.5% for Stages III, IVA (T-Ex group), and II (N-Ex group), respectively. The DSS and DFS did not differ for Stages III and IVA (T-Ex group) and II (N-Ex group). The prognoses of the N-Ex subgroups and the older T-Ex group did not also differ.
The patients aged 55 years or older without DM had comparable prognoses, although cases with N-Ex without T-Ex were classified as Stage II, and those with T-Ex were classified as Stage III or IVA. The recurrence rates for the N-Ex and T-Ex stages were also comparable. These suggest that N-Ex is an important prognostic factor.
美国癌症联合委员会(AJCC)第8版甲状腺乳头状癌(PTC)分期系统因某些淋巴结特征对预后影响的证据不足,未将其纳入分期决定因素。本研究旨在通过比较甲状腺外侵犯(T-Ex)和淋巴结外侵犯(N-Ex)病例的预后,探讨大体淋巴结外侵犯(N-Ex)对生存和复发的影响。
选取接受初次手术治疗且有T-Ex或N-Ex的PTC患者。比较他们的生存率和复发率,重点关注年龄和分期分类。年龄小于55岁且无远处转移(DM)的患者,无论有无T-Ex或N-Ex,均分类为I期。年龄55岁及以上且无DM的患者,若仅有N-Ex而无T-Ex则分类为II期,若有T-Ex则分类为III期或IVA期。比较按年龄分层的T-Ex组和N-Ex组的预后。根据器官受累情况进行T分类,对年龄较大的N-Ex患者进行亚组划分,并将其预后与T-Ex组进行比较。
本研究纳入183例T-Ex患者和50例无T-Ex的N-Ex患者。两组中无远处转移的年轻患者(两组均为I期)的疾病特异性生存率(DSS)和无病生存率(DFS)无差异。对于无远处转移的老年患者,III期和IVA期(T4bAnyNM0;T-Ex组)的10年DSS为80.6%和48.5%,II期(T1-3N-ExM0;N-Ex组)为74.7%。III期、IVA期(T-Ex组)和II期(N-Ex组)的10年DFS分别为68.2%、0%和64.5%。III期和IVA期(T-Ex组)与II期(N-Ex组)的DSS和DFS无差异。N-Ex亚组和老年T-Ex组的预后也无差异。
年龄55岁及以上且无DM的患者预后相当,尽管仅有N-Ex而无T-Ex的病例分类为II期,有T-Ex的病例分类为III期或IVA期。N-Ex期和T-Ex期的复发率也相当。这些表明N-Ex是一个重要的预后因素。